India · Delayed Price · Currency is INR Ajanta Pharma Statistics
Total Valuation
Ajanta Pharma has a market cap or net worth of INR 415.66 billion. The enterprise value is 410.40 billion.
| Market Cap | 415.66B |
| Enterprise Value | 410.40B |
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Aug 5, 2026 |
Share Statistics
Ajanta Pharma has 124.94 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Current Share Class | 124.94M |
| Shares Outstanding | 124.94M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 42.19% |
| Owned by Institutions (%) | 22.34% |
| Float | 42.05M |
Valuation Ratios
The trailing PE ratio is 32.93 and the forward PE ratio is 30.20. Ajanta Pharma's PEG ratio is 1.68.
| PE Ratio | 32.93 |
| Forward PE | 30.20 |
| PS Ratio | 6.69 |
| PB Ratio | 8.56 |
| P/TBV Ratio | 8.64 |
| P/FCF Ratio | 76.40 |
| P/OCF Ratio | 41.78 |
| PEG Ratio | 1.68 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.51, with an EV/FCF ratio of 75.43.
| EV / Earnings | 32.50 |
| EV / Sales | 6.60 |
| EV / EBITDA | 23.51 |
| EV / EBIT | 26.14 |
| EV / FCF | 75.43 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.85 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.09 |
| Debt / FCF | 0.28 |
| Interest Coverage | 121.91 |
Financial Efficiency
Return on equity (ROE) is 27.53% and return on invested capital (ROIC) is 27.77%.
| Return on Equity (ROE) | 27.53% |
| Return on Assets (ROA) | 16.22% |
| Return on Invested Capital (ROIC) | 27.77% |
| Return on Capital Employed (ROCE) | 30.90% |
| Weighted Average Cost of Capital (WACC) | 5.54% |
| Revenue Per Employee | 5.97M |
| Profits Per Employee | 1.21M |
| Employee Count | 10,421 |
| Asset Turnover | 1.03 |
| Inventory Turnover | 1.56 |
Taxes
In the past 12 months, Ajanta Pharma has paid 4.25 billion in taxes.
| Income Tax | 4.25B |
| Effective Tax Rate | 25.17% |
Stock Price Statistics
The stock price has increased by +29.07% in the last 52 weeks. The beta is 0.23, so Ajanta Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +29.07% |
| 50-Day Moving Average | 3,443.05 |
| 200-Day Moving Average | 3,192.00 |
| Relative Strength Index (RSI) | 44.44 |
| Average Volume (20 Days) | 170,713 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajanta Pharma had revenue of INR 62.17 billion and earned 12.63 billion in profits. Earnings per share was 101.02.
| Revenue | 62.17B |
| Gross Profit | 48.32B |
| Operating Income | 15.70B |
| Pretax Income | 16.88B |
| Net Income | 12.63B |
| EBITDA | 17.33B |
| EBIT | 15.70B |
| Earnings Per Share (EPS) | 101.02 |
Balance Sheet
The company has 6.80 billion in cash and 1.54 billion in debt, with a net cash position of 5.26 billion or 42.09 per share.
| Cash & Cash Equivalents | 6.80B |
| Total Debt | 1.54B |
| Net Cash | 5.26B |
| Net Cash Per Share | 42.09 |
| Equity (Book Value) | 48.58B |
| Book Value Per Share | 388.90 |
| Working Capital | 24.80B |
Cash Flow
In the last 12 months, operating cash flow was 9.95 billion and capital expenditures -4.51 billion, giving a free cash flow of 5.44 billion.
| Operating Cash Flow | 9.95B |
| Capital Expenditures | -4.51B |
| Depreciation & Amortization | 1.63B |
| Net Borrowing | -1.02B |
| Free Cash Flow | 5.44B |
| FCF Per Share | 43.55 |
Margins
Gross margin is 77.73%, with operating and profit margins of 25.26% and 20.31%.
| Gross Margin | 77.73% |
| Operating Margin | 25.26% |
| Pretax Margin | 27.15% |
| Profit Margin | 20.31% |
| EBITDA Margin | 27.88% |
| EBIT Margin | 25.26% |
| FCF Margin | 8.75% |
Dividends & Yields
This stock pays an annual dividend of 28.00, which amounts to a dividend yield of 0.84%.
| Dividend Per Share | 28.00 |
| Dividend Yield | 0.84% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 59.34% |
| FCF Payout Ratio | 137.78% |
| Buyback Yield | -0.05% |
| Shareholder Yield | 0.79% |
| Earnings Yield | 3.04% |
| FCF Yield | 1.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Ajanta Pharma is 3,865.77, which is 16.19% higher than the current price. The consensus rating is "Buy".
| Price Target | 3,865.77 |
| Price Target Difference | 16.19% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 14.49% |
| EPS Growth Forecast (3Y) | 16.97% |
Stock Splits
The last stock split was on June 22, 2022. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 22, 2022 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |